Watch CLDI. Know when insiders buy.
One email the day a filing lands. Free.
CLDI
Calidi Biotherapeutics, Inc.
1.36
+0.01 +0.74%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$17.5MNET CASH $9M52W 1.27 – 26.72SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4.2M | −$4.2M | — | -2.94 | −$4.4M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$4.2M | −$4.1M | — | -0.43 | −$4.1M | — | — | May 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$4.5M | −$4.1M | — | 0.45 | −$5M | — | — | Mar 27 |
| Q3 2025 · Sep 30 | — | — | — | −$5M | −$5.1M | — | -2.21 | −$4.2M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$5.7M | −$5.7M | — | -31.75 | −$4.9M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$5.1M | −$5M | — | -2.21 | −$7.1M | — | — | May 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$4M | −$4.1M | — | 6.70 | −$5.4M | — | — | Mar 27 |
| Q3 2024 · Sep 30 | — | — | — | −$5.2M | −$5.1M | — | -7.75 | −$4.9M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$5.8M | −$5.8M | — | -16.75 | −$5.5M | — | — | Aug 8 |
| Q1 2024 · Mar 31 | — | — | — | −$6.8M | −$7.2M | — | -2.03 | −$3.8M | — | — | May 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$9.8M | −$8.2M | — | 2.47 | −$5.2M | — | — | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$7.2M | −$2M | — | -1.41 | −$13.5M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$20.2M | −$19.9M | — | -5.95 | −$21.3M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$21.8M | −$22.1M | — | -35.70 | −$19.7M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$29M | −$29.2M | — | -17.33 | −$27M | — | — | — | — |
| FY2022 · to Dec 31 | $45K | — | −$23.1M | −$25.4M | -56504.4% | 2.99 | −$13.2M | — | — | — | — |
Every number comes from Calidi Biotherapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.